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Abstract: Human helminthiases are of considerable public
health importance in sub-Saharan Africa, Asia, and Latin
America. The acknowledgement of the disease burden due
to helminth infections, the availability of donated or
affordable drugs that are mostly safe and moderately
efficacious, and the implementation of viable mass drug
administration (MDA) interventions have prompted the
establishment of various large-scale control and elimination
programmes. These programmes have benefited from
improved epidemiological mapping of the infections, better
understanding of the scope and limitations of currently
available diagnostics and of the relationship between
infection and morbidity, feasibility of community-directed
or school-based interventions, and advances in the design of
monitoring and evaluation (M&E) protocols. Considerable
success has been achieved in reducing morbidity or
suppressing transmission in a number of settings, whilst
challenges remain in many others. Some of the obstacles
include the lack of diagnostic tools appropriate to the
changing requirements of ongoing interventions and
elimination settings; the reliance on a handful of drugs
about which not enough is known regarding modes of
action, modes of resistance, and optimal dosage singly or in
combination; the difficulties in sustaining adequate coverage
and compliance in prolonged and/or integrated pro-
grammes; an incomplete understanding of the social,
behavioural, and environmental determinants of infection;
and last, but not least, very little investment in research and
development (R&D). The Disease Reference Group on
Helminth Infections (DRG4), established in 2009 by the
Special Programme for Research and Training in Tropical
Diseases (TDR), was given the mandate to undertake a
comprehensive review of recent advances in helminthiases
research, identify research gaps, and rank priorities for an
R&D agenda for the control and elimination of these
infections. This review presents the processes undertaken
to identify and rank ten top research priorities; discusses the
implications of realising these priorities in terms of their
potential for improving global health and achieving the
Millennium Development Goals (MDGs); outlines salient
research funding needs; and introduces the series of reviews
that follow in this PLoS Neglected Tropical Diseases collection,
‘‘A Research Agenda for Helminth Disease .’’
Introduction
Human helminthiases affect mostly populations in sub-Saharan
Africa, Asia, and the Americas [1]. The affected populations are
typically largely marginalised, live in low-income settings, and
account for over 1 billion people infected with one or more
helminth species. These infections are associated with low work
productivity, poor cognitive performance, and slow socioeconomic
development, thereby contributing to accentuate poverty and
inequality [1,2]. Despite their insidious effects at the individual
and societal levels, helminth infections and their associated disease
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o Humans s  f sequelae have not received as much research and investment
attention as other acute or life-threatening conditions, a fact that
has placed human helminthiases in the category of neglected
tropical diseases (NTDs). However, the collective morbidity that
these diseases cause is considerable and comparable to that caused
by malaria, HIV/AIDS, or tuberculosis [2], and they are also
responsible for excess mortality [3–5].
Consequently, over the past three decades (straddling the last
quarter of the 20th century and the first decade of this century),
increased acknowledgement of the impact of their burden on
human communities has led to an expansion of the number of
large-scale control and elimination programmes against helminth
infections, aiming to eliminate the public health problem they pose
(morbidity reduction), or the infection reservoir (parasite elimina-
tion). The relatively limited arsenal of available tools for
intervention against helminthiases, the extent and heterogeneity
of their geographic distribution, and the sheer magnitude of the
overall task, have meant that morbidity control rather than
parasite elimination has been the initial target for most
programmes. Examples of these, mostly vertical, single-disease
interventions are the Onchocerciasis Control Programme in West
Africa (OCP), the African Programme for Onchocerciasis Control
(APOC), the Schistosomiasis Control Initiative (SCI), and the
Partners for Parasite Control (PPC). Exceptions to this are those
campaigns that started with a clear mandate of eradication (e.g.,
Guinea Worm Eradication Programme) or parasite elimination
(the Joint Research Management Committee [JRMC] for
Schistosomiasis Elimination in China, the Global Programme to
Eliminate Lymphatic Filariasis [GPELF], and the Onchocerciasis
Elimination Program for the Americas [OEPA]). However, as
morbidity reduction initiatives advance, their goals have become
more ambitious, aiming at elimination where deemed feasible.
Multiple helminth infections, affecting the same populations
parasitised by more than one species, are also common [5],
though the burden of disease due to co-morbidity remains largely
unknown [6]. The increased recognition of this co-endemicity and
polyparasitism has prompted the establishment of integrated,
multi-helminth, and multi-NTD control strategies.
Whilst this shift in focus is understandable (essentially indefinite
programmes risk fatigue of sponsors and populations, and there is
a need to optimise efforts and resources), the question remains as
to whether the scientific and public health communities truly have
the knowledge and the tools matched to the task of controlling/
eliminating human helminthiases regionally, globally, and in an
integrated manner. It is with the objective of contributing to
answering this question that the Disease Reference Group on
Helminth Infections (DRG4) was established by the Special
Programme for Research and Training in Tropical Diseases
(TDR). The infections within the remit of this group include the
filariases (onchocerciasis and lymphatic filariasis), trematodiases
(intestinal and urinary schistosomiasis; food-borne, liver fluke
infections), the soil-transmitted helminthiases (intestinal nematode
infections), and cestode infections (taeniasis/cysticercosis). (Note
that some of these infections are zoonoses [e.g., Asian schistoso-
miasis, food-borne trematodiases, taeniasis/cysticercosis] and
recognised under the umbrella of neglected zoonotic diseases
[NZDs] by the first World Health Organization [WHO] report on
NTDs [7]. The various aspects of veterinary public health as one
of the pivotal strategies for the prevention and control of NZDs
have been discussed by DRG6 [Table S1] and summarised in
their recent review [8], and therefore are not addressed extensively
by DRG4.)
Firstly, some key research findings leading to (or stemming
from) the establishment of some of the above mentioned
programmes are outlined (for further detail on the problem of
helminthiases, large-scale control programmes past and present,
and available tools for intervention against these infections, see
Lustigman et al. [9] and Prichard et al. [10] in this collection of
reviews). Secondly, the DRG4 is introduced, and the processes
that the group used to identify research gaps and key priority
research areas are described. Finally, some of the issues that
challenge sustained control and elimination of helminthiases are
discussed, and the rationale is presented for the review articles
contained within this PLoS Neglected Tropical Diseases collection, ‘‘A
Research Agenda for Helminth Diseases of Humans’’. Box 1 lists
the abbreviations used in this article.
Research for Control and Elimination of Human
Helminthiases
Undoubtedly, there has been much scientific advancement in
our understanding of the biology and epidemiology of helminth
infections that has underpinned control efforts. For the OCP, early
research on Onchocerca–Simulium complexes, on epidemiological
and parasite heterogeneity regarding blindness patterns [11], and
on cytotaxonomy, distribution, ecology, and flight range of the
various members of the Simulium damnosum complex [12] helped to
demarcate original areas under (vector) control and further
extensions. Importantly, operations research has been crucial to
solving some of the programmatic issues confronted by the
programmes throughout their implementation, such as the
development of insecticide resistance and reinvasion of areas
under control by infective flies [13]. (In the context of this paper
[and others in this collection], operations research is used to refer
to the utilisation of relevant biological knowledge and appropriate
and updated technologies by large-scale parasite control initiatives
Box 1. List of Abbreviations
APOC, African Programme for Onchocerciasis Control
DALY, disability-adjusted life year
DRG4, Disease Reference Group on Helminth Infections
G-FINDER, Global Funding of Innovation for Neglected
Diseases
GPELF, Global Programme to Eliminate Lymphatic Filari-
asis
JRMC, Joint Research Management Committee for
Schistosomiasis Elimination in China
LF, lymphatic filariasis
MDA, mass drug administration
MDGs, Millennium Development Goals
M&E, monitoring and evaluation
NTDs, neglected tropical diseases
NZDs, neglected zoonotic diseases
OCP, Onchocerciasis Control Programme in West Africa
OEPA, Onchocerciasis Elimination Program for the Amer-
icas
PAHO, Pan American Health Organization
PPC, Partners for Parasite Control
SCI, Schistosomiasis Control Initiative
R&D, research and development
STHs, soil-transmitted helminthiases
TDR, Special Programme for Research and Training in
Tropical Diseases
UNICEF, United Nations Children’s Fund (formerly United
Nations International Children’s Emergency Fund)
UNDP, United Nations Development Programme
WHO, World Health Organization
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reduce the parasite burden, transmission, and morbidity of
poverty-related infectious diseases in general and helminthiases
in particular.)
A further example is that of the licensing of ivermectin for
human use in 1987, and its subsequent donation by Merck & Co.
for as long as needed against river blindness, which prompted
research into the ‘‘why’’, ‘‘where’’, and ‘‘how’’ to control
onchocerciasis on a large scale with chemotherapy in addition to
vector control or as the only measure being implemented [14].
Consequently, research on the social importance of onchocercal
skin disease provided the justification for extending control to
other endemic areas outside the savanna regions of West Africa,
where blindness had been the major motivation for control by the
OCP. This extension made it possible for millions of people to
benefit from the control efforts implemented by APOC. The
development of the rapid epidemiological assessment and mapping
methods that ensued [15–17] also facilitated demarcation of areas
prioritised for ivermectin distribution (e.g., meso- and hyperen-
demic areas), and more recently, identification of areas where
specific management strategies or novel control tools are needed
(e.g., areas co-endemic for onchocerciasis and loiasis with a high
risk of severe adverse events if ivermectin is administered) [18].
Sensitive and specific parasite antigen tests for Wuchereria
bancrofti, developed in a rapid card format, made the mapping of
the distribution of Bancroftian filariasis operationally feasible [19].
This, together with the donation or affordability of drugs for safe
mass administration in combinations highly efficacious against the
microfilariae and affecting the adult worms to a lesser extent (but
importantly, prolonging the period when the density of microfi-
lariae, which can be transmitted to vectors, remains low),
promoted the idea that elimination of lymphatic filariasis (LF)
was attainable as a public health goal [20]. As the GPELF has
advanced, and challenges have been encountered, priority areas
for programmatic research have been articulated, including 1)
refinement of tools and evidence-based measurements of pro-
gramme success for stopping mass treatment in diverse settings
and according to vector–parasite complexes; 2) increased efforts to
enhance programme effectiveness by improving MDA coverage
and compliance, using vector control where feasible, and
integrating with other programmes where appropriate; 3)
improved clinical management for individuals with LF disease;
and 4) protection of the LF programme by monitoring drug
resistance and developing new drugs [21,22].
Forschistosomiasis, accessto clean waterand adequate sanitation
systems, snail (intermediate host) control, and treatment of
infections in humans (and other mammalian hosts where possible)
are the major intervention tools. However, water and sanitation are
still lacking in many of the poorest communities, and molluscicides
are difficult to use and often environmentally unacceptable.
Therefore, ‘‘preventative chemotherapy’’, aimed at reducing the
intensityof infectionandsubsequent morbidity, hasbecomethe tool
of choice [23]. Currently, preventative chemotherapy is recom-
mended by the WHO against schistosomiasis and soil-transmitted
helminthiases (STHs) [24]. The SCI adopted integrated schistoso-
miasis and intestinal worm control in their strategy to support
national control programmes in sub-Saharan Africa [23]. The SCI
hasembedded researchintothisstrategyfromtheoutset,supporting
the mapping of the infections in the participating countries [25];
developing appropriate protocols for monitoring and evaluation
(M&E)[26];usingmathematicalmodelsforquantification ofimpact
[27]; investigating parasite population genetic structure and the
possibility of drug resistance [28], and furthering understanding of
the relationship between infection and morbidity indicators [29].
For other diseases under our remit (e.g., food-borne trematodiases
and taeniasis/cysticercosis), we refer the readers to [7–10], and the
‘‘One Health’’ approach that has been promoted extensively in the
past couple of years as an essential way to control and eliminate
zoonotic infections [30].
Despite the pivotal role that basic and operations research has
obviously played towards the attainment of helminthiasis control
and elimination, the current research and development (R&D)
agenda for these infections, let alone the funding to pursue it, is still
insufficient, another feature of the NTDs. Most programmes face
major deficiencies in the availability of novel intervention and
diagnostic tools, and in the fundamental knowledge of helminth
biology that can serve as a platform from which to implement
strategies for optimal combination of existing interventions, and to
help with the development of the novel tools that are required.
The Disease Reference Group on Helminth
Infections (DRG4)
TDR has a 10-year strategy (http://www.who.int/tdr/about/
strategy/en/) to foster ‘‘an effective global research effort on
infectious diseases of poverty in which disease-endemic countries
play a pivotal role’’ [31]. As part of this strategy, TDR has
established a global research ‘‘think-tank’’ of 125 international
experts grouped into ten thematic and disease-specific groups to
review evidence continually and systematically, assess research
needs and, following periodic national and regional stakeholder
consultations, set research priorities for accelerating the control of
infectious diseases of poverty. Working in ten disease-specific and
thematic reference groups (DRGs/TRGs; Table S1), one of which
is the DRG4, these experts are crucial contributors to TDR’s
stewardship mandate for the acquisition and analysis of informa-
tion on infectious diseases of poverty (http://whqlibdoc.who.int/
hq/2007/TDR_GEN_07.1_EN_Rev.1_eng.pdf). Their work is
ultimately intended to promote control-relevant research, achieve
research innovation, and enhance the capacity of disease-endemic
countries to tackle public health problems related to the
disproportionate burden of infectious diseases among the poor.
The DRG4 started with 14 members (the authors of this
review), recognised as academic or public health leaders selected
from research institutions, international bodies, public health
organisations, and governmental organisations. (The group is
chaired by SL, co-chaired by BAB, MYO-A is the Career
Research Fellow, and the Core Writing Group comprises SL, M-
GB, RKP, and BAB.) Its mandate is to a) obtain, evaluate, and
synthesise scientific information on global research activities and
challenges in research on helminth infections and other emerging
helminth diseases of public health importance encompassing
onchocerciasis, LF, STHs, schistosomiasis, food-borne tremato-
diases, and taeniasis/cysticercosis; b) act as a think tank for
research on helminth diseases of public health importance,
including advocacy; c) communicate their findings and recom-
mendations on a regular basis via shared communities-of-practice
(e.g., http://www.TropIKA.net and/or other appropriate, open-
access publication forums); d) develop and implement a workplan
according to the TDR General Operations Guide of Disease-
Specific (DRG) and Thematic Reference Groups (TRG) for
Research on Infectious Diseases of Poverty; and e) prepare annual
reports for peer-review and future use on http://www.TropIKA.
net and/or others, and for the Global Report for Research
on Infectious Diseases of Poverty (http://www.who.int/tdr/
stewardship/global_report/en/index.html).
In preparation for the first meeting of the DRG4 in Burkina
Faso, in January 2010, all members of the group were asked to
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rising scientific information on current activities in global research
on helminth infections; highlighting progress; identifying knowl-
edge gaps, needs, and challenges; and suggesting priorities for
future global research based on four questions: what is known;
what (existing) research has not been used or applied; what is not
known; and what research is needed. Text S1 describes the
meetings of the group, the stakeholder consultations that preceded
these meetings, and the methodology used for identification,
prioritisation, and ranking of research gaps.
At the Burkina Faso meeting, five main core themes of 1)
interventions, 2) epidemiology and surveillance, 3) environmental
and social ecology, 4) data and modelling, and 5) basic
(fundamental) biology (Figure 1) were identified as umbrella
priorities to further support the control and elimination of
helminthiases. Other themes within these umbrella priorities were
also identified, and three areas—advocacy, integration, and
innovation—cutting across all five core themes were considered
(Figure 1). It was clear that within each of the core themes issues at
global, regional, national, and local levels needed to be addressed.
Box 2 lists the underlying values and criteria for ranking that were
followed to prioritise research gaps, and Table 1 presents the ten
top priority research areas identified. A league table (Table S3) was
prepared for the ten priority research areas as described in Text
S1. Text S2 presents the projected time horizons for the
achievement of the priority research areas identified and discusses
their potential impact on global health and the attainment of the
Millennium Development Goals (MDGs). The outcomes are
summarised in Table S4.
Challenges in the Control and Elimination of
Human Helminthiasis
Although there has been much progress in the research and
control of human helminthiases [32–38], and in addressing the
operational issues and research needs that arise during the
implementation of the programmes [39], major obstacles remain
that challenge the global public health community and for which
fundamental and applied research is urgently needed. The
following outlines salient areas that will be covered in greater
depth, together with others, in the reviews presented in this
collection.
Mapping
There is a need for more accurate and updated disease
mapping. An example is that of LF, for which the tools available
for rapid assessment of infection prevalence (immunochromato-
graphic card tests for detection of circulating filarial antigen) and
incorporation of areas into the GPELF (when prevalence surpasses
1%) have proven unreliable under field conditions [40,41]. The
advent of geographical information systems, more accurate
national and regional mapping of infections, and the application
of model-based geostatistics have helped various programmes to
demarcate areas in need of control [42]. These maps, however,
should be dynamic entities that change with time as control
progresses, necessitating refinement of tools for updating the
original disease maps (e.g., through linking geostatistical with
transmission dynamics models).
Diagnostics
Current diagnostics, as used in field and routine settings,
provide rather inaccurate (and indirect) measures of infection
prevalence and intensity that are subject to a great deal of
variability and measurement error. Yet, they provide the basis for
most of the epidemiological assessment upon which control
programmes are based, and for assessment of drug efficacy by
phenotypic means. Following several years of control and
elimination programmes the problem compounds, as average
infection levels will have fallen to very low levels, masking
increased heterogeneity and making it difficult to distinguish true
absence of infection from false negatives. There is a need to better
account for variability in infection measures [43], compare and
optimise (including comparative costs in operational settings) the
diagnostic performance of currently available tests for epidemio-
logical and drug efficacy monitoring [44–46], and to develop novel
assays that respond to the changing needs of ongoing control
programmes [47].
Monitoring and Evaluation (M&E) and Surveillance
Most programmes require demonstrable evidence of impact,
either as vertical programmes delivered by mobile teams,
community-directed interventions, or integrated programmes with
other NTD and infectious disease interventions. There is a need to
design robust cohort studies that allow quantification of changes in
incidence of infection [27] and disease [48]; to develop and cost
sampling protocols for integrated interventions in co-endemic
areas [49,50]; to assess drug efficacy and develop genetic markers
for investigation of parasite population structure and possible
changes effected by chemotherapeutic pressure [51–53]; to
optimise and develop diagnostic and analytical (quantitative) tools
for determination of programme endpoints (for elimination of the
public health burden and/or the infection reservoir) [54]; and to
implement systems for surveillance [55]. Mathematical models can
Box 2. Underlying Values and Criteria for
Ranking Research Areas
Underlying values
N Curative or preventative relevance at patient/community
level
N Public health relevance/impact on population health
N Pro-poor/poverty alleviation
N Millennium Development Goals and/or other relevant
global targets
N Health security relevance
N Inter-sectoral
N Equity/gender and equity/social justice
N Positive risk-benefit ratio
N Feasibility
N Universality
N Global public good
N Innovation
Criteria for ranking
N Potential public health impact (by disease burden
reduction)
N Size of population benefiting from research
N Feasibility (Cost benefit)
N Economic implications (Cost effectiveness)
N Equity implications
N Equality implications
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[56], and elimination efforts in a variety of settings [57].
Coverage of and Adherence to the Interventions
Optimum intervention coverage (with MDA and/or any other
intervention such as vector or snail control) is required for the
success of control or elimination programmes. Intervention
coverage is a key determinant for the programmes to achieve
their targets [58]. However, in several countries (e.g., India), a gap
between coverage and compliance has been observed in the
treatment of LF [59]. The contribution of non-compliant
individuals to transmission has not been quantified but it could
be considerable (for instance, if those who do not adhere to
treatment are heavily infected individuals who experienced
unpleasant side effects on first treatment), and systematic non-
compliance represents a potential threat to elimination. Research
to understand the determinants of compliance in conjunction with
studies on socio-behavioural, educational, and political drivers of
programme acceptability and adherence [60,61] is urgently
required given the prolonged duration of intervention that is
often needed. This is also important given the increasing trend for
integrating control programmes that target multiple infections.
Integration of interventions, at least in the initial phases of
transition from well-run vertical programmes to integrated
programmes, may temporarily decrease coverage [22,61], but
see [62].
Modes of Delivery
Current MDA strategies are more suited to rural communities.
It has been argued that the structures in rural, sedentary
communities favour this type of approach, particularly when
interventions are community directed [62]. However, a large
number of helminth diseases also occur in urban areas and in
pastoral and nomadic populations, as well as in conflict and post-
conflict areas. The social and cultural structures in these groups of
populations and areas are quite different from those in the rural
situation. It will be important to undertake operations research to
determine the best strategies for MDA and morbidity manage-
ment in such groups.
Intervention Tools
The donation by pharmaceutical companies of broad-spectrum
anthelmintics (ivermectin, albendazole, mebendazole), the in-
creased affordability of generic drugs produced in disease-endemic
countries (diethylcarbamazine, praziquantel) in comparison with
(seemingly) more expensive and cumbersome vector or interme-
Figure 1. Five major core themes identified by DRG4. Umbrella priorities identified by the Disease Reference Group on Helminth Infections
(DRG4) for the control and elimination of human helminthiases under its remit, namely, onchocerciasis, lymphatic filariasis, schistosomiasis, soil-
transmitted helminthiases, food-borne trematodiases, and taeniasis/cysticercosis.
doi:10.1371/journal.pntd.0001547.g001
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economic development in many endemic areas, have made
preventative chemotherapy the cornerstone of helminth control.
However, the reliance on very few drugs (mainly developed against
parasites of veterinary importance rather than for treatment of
humans), the fact that most drugs fall short of being highly
efficacious and in some cases (the filarial nematodes) do not kill the
adult worms, and that dosages, combinations, and frequency of
administration have not, by and large, been optimised, means that
programmes lack the best tools for the job [63,64]. There is an
urgent need for a macrofilaricidal drug or drug combinations for
onchocerciasis and LF. Antibiotic treatment regimes that deplete
these parasites of their bacterial (Wolbachia) endosymbionts have
shown promising results by leading to adult worm mortality/
sterility [65], but the length of treatment that is required and the
contraindications that apply at present make current regimens less
suitable for community-directed intervention (but see [66]). Vector
control, in combination with anthelmintic treatment, can play an
important role in reducing vector density to levels below threshold
biting rates and therefore aid elimination, reduce reinfection rates
and programme duration, and help minimise the spread of
anthelmintic resistance [67–69]. Integration of anthelmintic and
antimalarial interventions can make use of the fact that in some
areas both Plasmodium spp. and W. bancrofti are transmitted by the
same Anopheles mosquito species, so vector control for malaria can
have an impact on LF transmission [70], and distribution of
anthelmintic treatment (e.g., ivermectin) in areas co-endemic for
LF and/or onchocerciasis and malaria may have an impact on
malaria transmission [71]. Research is needed to determine
optimal combinations of anthelmintics in particular and interven-
tions in general, and mathematical models can help in assessing
these for a variety of epidemiological scenarios, endemicity levels,
transmission intensities, and vector species composition, as has
been done in malaria [72].
Funding for Research and Development (R&D)
The G-FINDER (Global Funding of Innovation for Neglected
Diseases) survey published in 2009 [73], reviewed by Moran et al.
[74], and updated in 2010 [75], aims to report accurate and
comparable R&D investment figures for infectious diseases of
poverty, contrasting the ‘‘Big Three’’ (HIV, tuberculosis, and
malaria) with the NTDs. The report noted that research funding is
highly concentrated towards the former, but not necessarily
correlated with disease burden. For instance, HIV, tuberculosis,
and malaria accounted for 125 million disability-adjusted life years
(DALYs) in low- and middle-income countries in 2004, and
received nearly 80% of the total funding. By contrast, pneumonia
and diarrhoeal diseases accounted for 165 million DALYs in the
same countries and year, yet received less than 6% of the total
funding. In particular, helminth infections received less than half
the funding for diseases caused by kinetoplastid protozoans
(leishmaniasis and trypanosomiasis), although their disease burden
was three times as high (12 million DALYs in 2004 for the
helminthiases compared to 4 million DALYs for the infections
caused by these protozoans). In the G-FINDER survey, R&D
products include drugs, vaccines (preventative and therapeutic),
Table 1. The Top Ten Priority Research Areas Identified by DRG4.
Core Theme
a Priority
b Description of Priority
(1) 1 Optimise existing intervention tools to maximise impact (taking into account polyparasitism) and sustainability. The tools include
pharmaceuticals, vaccines, vector control, and eco-health approaches (access to clean water and sanitation, improved nutrition,
education). Sustainability depends on minimising selection for drug resistance and maintaining community support for adequate
coverage and compliance.
2 Develop novel control tools that will improve impact and sustainability. The tools include new pharmaceuticals, vaccines, vector
control methods, and eco-health approaches.
(2) 3 Improve existing/develop novel diagnostic tests, with particular reference to their performance regarding sensitivity, specificity,
multiplex capacity, and ability to measure infection intensity/active infection. Sensitivity and specificity are mostly important to
enable diagnosis of infection at low prevalence in elimination settings and to confirm cure/absence of particular infection.
4 Standardise and validate methodologies and protocols for diagnosis in monitoring and evaluation (M&E) settings.
(1, 3) 5 Develop strategies incorporating delivery of multiple and combinations of interventions at various (individual, community,
district, national) levels to maximise sustainability of control programmes in general and of integrated control programmes in
particular.
(3) 6 Develop strategies (taking gender issues into account) to increase community participation, ownership, and empowerment, as
well as equity in access by communities and risk groups to health services.
(4) 7 Develop and refine mathematical models to investigate relationships between infection and morbidities to aid programmes
aiming to reduce the burden of disease (elimination of public health problem). Such models need to take into account
cumulative effects of chronic disease for evaluation of disease burden and the impact on such burden of control interventions.
8 Increase use and application of mathematical models to aid M&E, surveillance, elimination efforts, and the design of sampling
protocols as well as the monitoring of intervention efficacy, including drug resistance. These models should be linked to
economic impact studies of the diseases and cost-effectiveness analyses of the interventions, their combinations, and their
alternatives.
(5) 9 Define the determinants and impact of parasite modulation of the host–parasite relationship, including impact on the host
response to concurrent infection with other helminth and non-helminth pathogens and to vaccination, and parasite responses,
including immune responses to interventions.
10 Annotate parasite genomes and transcriptomes and develop tools for parasite functional genomics (and other ‘‘omics’’) in key
species.
aCore themes are (1) control interventions; (2) epidemiology and surveillance; (3) environmental and social ecology; (4) data and modelling; (5) basic (fundamental)
biology (see Figure 1).
bNumbering of the ten top priories does not reflect order of importance; instead, they are organised according to core theme; all the (inter-connected) priorities are to
be addressed in parallel as each priority will benefit from accomplishing the others.
doi:10.1371/journal.pntd.0001547.t001
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control agents, and vaccines targeting animal reservoirs); and
platform technologies (adjuvants, diagnostic platforms, and
delivery devices). Helminth infections specifically were considered
to require the following range of R&D activities: basic research
and drugs for all listed infections (schistosomiasis, LF, onchocer-
ciasis, STHs, taeniasis/cysticercosis); vaccines and novel diagnos-
tics for schistosomiasis, onchocerciasis, strongyloidiasis, and
hookworm infection; and vector/intermediate host control
products for schistosomiasis, onchocerciasis, LF, and taeniasis.
Although the proportion of total R&D funding allocated to
helminthiases has shown a slight upwards trend (2.0% in 2007,
2.3% in 2008, 2.5% in 2009) [75], investment dwarfs in
comparison to the 72% corresponding to the Big Three,
positioning helminth infections in the 7th place of the R&D
investment ranking table, preceded by HIV, malaria, tuberculosis,
diarrhoeal diseases, dengue, and leishmaniasis/trypanosomiasis
[75].
Lack of knowledge of the health and socioeconomic impact of
helminth diseases, and appropriate appraisal of the cost-effective-
ness of control interventions, is generally one of the biggest
obstacles to obtaining funds for investment in basic and applied
research [76]. Although many examples of highly cost-effective
interventions to control helminth diseases exist, our understanding
of the full economic effect that these diseases have on individuals,
households, and nations remains incomplete [77], and is
particularly scanty regarding, for instance, the food-borne
trematodiases (e.g., the recent and excellent review by Conteh
et al. [77] does not include data on these infections in their table
on economic costs of selected NTDs). One of the obstacles to
assessing the overall burden of helminth disease is its reliance on
the DALY metrics, whose main determinant is the mortality rate.
Instead, helminth diseases are characterised by a lifetime of
disablement. Therefore, DALYs do not adequately quantify the
chronic nature of these diseases [6]. As DALY estimates currently
attributed to individual helminth diseases are deemed to be too
low, the incremental cost-effectiveness ratio of any economic
evaluation will be underestimated [77,78]. It is therefore essential
that estimates of numbers infected and disease burden are refined
and updated evidence is presented on the costs, cost-effectiveness,
and financing of different strategies to monitor, control, or reduce
morbidity and mortality associated with these diseases [77,79,80].
This problem is even more pronounced for the zoonotic
helminthiases, as there is a lack of reliable qualitative and
quantitative data on the burden of such diseases. Importantly,
these data need to go beyond the DALY to measure and
incorporate economic and health burdens resulting from produc-
tion losses due to disease in livestock [8,81].
A Research Agenda for Helminth Diseases of
Humans
The five core themes identified (Figure 1) form the basis of the
review articles prepared by DRG4 members for this PLoS Neglected
Tropical Diseases collection. The reviews are intended to discuss in
depth the issues pertaining to each of the umbrella priorities and
expand on the research gaps and needs, presenting a detailed
R&D agenda for human helminthiases for each of the core themes
that is beyond the scope of this introduction to the collection.
In the first review, ‘‘The Problem of Helminthiases’’, Sara
Lustigman and co-authors [9] discuss how the disproportionate
burden of disease caused by helminth infections in the poorest
communities contributes to a vicious cycle of infection, poverty,
decreased productivity, and inadequate socioeconomic develop-
ment. The review provides an overview of the forces driving the
persistence of helminthiases as a public health problem despite the
many control initiatives that have been put in place, identifies the
main obstacles that impede progress towards their control and
elimination, and discusses recent advances, opportunities, and
challenges for the understanding of the biology, epidemiology, and
control of these infections.
In the second review, ‘‘Intervention for Control and Elimina-
tion’’, Roger Prichard and co-authors [10] discuss the status of
current intervention tools for the control and elimination of
helminth infections that are useful but not adequate in all settings.
Recent advances and remaining obstacles drive the need for an
R&D agenda to ensure that the appropriate interventions (drugs,
vaccines, vector control, environmental improvement) are avail-
able for use in helminth control and elimination in an optimised
and timely manner, that novel anthelmintics are developed, and
that resistance to drugs, insecticides, or vaccines is minimised.
In the third review, ‘‘Diagnostics for Control and Elimination
Programmes’’, James McCarthy and co-authors [82] discuss how
diagnostic tools appropriate for implementation, M&E, and
surveillance of interventions to control helminth infections are crucial
to their success. However, the development and implementation of
diagnostics has not been uniform across diseases. Pilot studies on
proof of concept of new and promising diagnostic technologies have
n o tb e e nf o l l o w e db ym u c hn e e d e dp r o d u c td e v e l o p m e n t ,s oi ns o m e
settings diagnosis continues to rely on insensitive and unsatisfactory
parasitological or serodiagnostic techniques. In this review, current
and under development diagnostic technologies for control and
elimination of helminth infection are reviewed and critical gaps and
opportunities are identified.
In the fourth review, ‘‘Social Ecology, Environmental Deter-
minants, and Health Systems’’, Andrea Gazzinelli and co-authors
[83] focus on the environmental, social, behavioural, and political
determinants of human helminth infections and outline a research
and development agenda for the socioeconomic and health
systems research required for the development of sustainable
control programmes. Factors related to poverty, migration, and
the environment (including ecological factors, climate change,
water resources, and housing conditions), as well as issues related
to polyparasitism, community participation, and equity in access
to health services (including gender, intersectoral collaboration,
and interdisciplinary research) are examined. It is concluded that
research on social and environmental determinants can contribute
significantly to the prevention and control of helminth diseases and
thus demands greater attention by the public health community.
In the fifth review, ‘‘Modelling for Control and Elimination’’,
Marı ´a-Gloria Basa ´n ˜ez and co-authors [84] argue that although
mathematical modelling of helminth infections has the potential to
inform policy and guide research for the control and elimination of
human helminthiases, this potential has yet to be realised. A
summary of the development of mathematical models for
helminthiases is presented and current efforts are discussed
according to the role that models can play at various stages of
control and elimination programmes. A research and development
agenda for helminthiasis modelling is proposed based on identified
gaps that need to be addressed for models to become useful decision
tools that can support research and control operations effectively.
In the sixth review, ‘‘Basic Research and Enabling Technologies
to Support Control and Elimination of Helminthiases’’, Sara
Lustigman and co-authors [85] discuss that although there has
been substantial scientific advancement in our understanding of
the basic biology of helminthiases, major research gaps still remain
that need to be addressed to improve and update fundamental
knowledge of helminth biology, and to translate such knowledge
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S. into novel intervention tools, namely, parasite genomics and
functional genomics, proteomics and metabolomics, helminth
immunology and (immuno)pathology, host–parasite–vector inter-
actions, and transmission biology.
In the seventh and final review, ‘‘Health Research and Capacity
Building in Disease-Endemic Countries for Helminthiases Con-
trol’’, Mike Y. Osei-Atweneboana and co-authors [86] discuss the
challenges confronting the building and maintenance of research
capacity in disease-endemic countries, the global, regional, and
national efforts and strategies towards establishing such research
capacity, and the implications of regional and national health
research policies on the control of helminthiases. The authors
conclude that strategies for building research capacity and
underlying policies are less than satisfactory in disease-endemic
countries, where North-South cooperation is typically stronger
than South-South collaboration. The various attempts to remedy
this situation through the consolidation of links between disease-
endemic regions, particularly in Africa, are discussed.
Conclusion
The major helminth control and elimination programmes past
and present have benefited from a substantial body of fundamental
and operations research that has contributed to the progress and
success of these programmes in the last three decades. In spite of
these advancements, research investment and development for
helminth infections has lagged behind the attention and resources
devoted to other infectious diseases. As a result, major deficiencies
exist in intervention and diagnostic tools that are appropriate to
the changing demands of the large-scale preventative chemother-
apy strategies that have become synonymous with helminth
control, in understanding the social epidemiology and environ-
mental ecology of these infections, in capitalising on the potential
that mathematical models have to offer as decision-support
instruments, and importantly, in the understanding of fundamen-
tal helminth biology that can open up avenues for novel targets
and for assessing the evolutionary implications of ongoing
interventions. The DRG4, through its TDR mandate, and in
consultation with other disease-specific and thematic groups, and
stakeholders, has identified, ranked, and projected in different time
horizons, ten top priority research areas (Table S3) considered to
be essential for the attainment of control and elimination efforts
against helminth infections of humans. These priority areas should
be addressed in parallel, as they are interconnected to one another
and each one would benefit from accomplishing the remainder.
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